In an initial inquiry of the existence of the prostate as an immunologically privileged site due to immunosuppressive properties of its secretory milieu as being contributory to the high incidence of occult prostatic carcinoma and wide variation in the age of onset of clinical disease, normal human seminal plasma was observed to suppress tumour-associated directed immunity in patients with prostatic cancer. In extending these initial observations, the effect of HuSP1 on a disease related activating or 'arming' factor in the sera of prostatic cancer patients has been evaluated.
|Original language||English (US)|
|Number of pages||1|
|Journal||IRCS Medical Science|
|State||Published - 1979|
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)